Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Immunovia AB ( (SE:IMMNOV) ).
Immunovia AB has announced a rights issue to raise approximately SEK 100 million, subject to approval at an Extraordinary General Meeting. The funds will be used to support the commercial launch of their new product, PancreaSure, and additional studies for reimbursement. The company has secured bridge loans to maintain liquidity and has received significant subscription intentions and guarantee commitments covering 80% of the rights issue. This move is part of Immunovia’s strategy to transform patient outcomes in pancreatic cancer detection, a critical area with low survival rates.
More about Immunovia AB
Immunovia AB is a company operating in the healthcare industry, focusing on the development of innovative diagnostic solutions. The company is primarily engaged in creating blood-based tests aimed at early detection of pancreatic cancer, addressing a significant unmet medical need.
Average Trading Volume: 7,956,228
Technical Sentiment Signal: Buy
Current Market Cap: SEK293.8M
Find detailed analytics on IMMNOV stock on TipRanks’ Stock Analysis page.